Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies

Vaccine

Volumn 25, Issue 45, 2007, Pages 7773-7784

  Stamataki, Zania ^a   Coates, Stephen ^b   Evans, Matthew J ^c   Wininger, Mark ^b   Crawford, Kevin ^b   Dong, Christine ^b   Fong, Yiu lian ^b   Chien, David ^b   Abrignani, Sergio ^b   Balfe, Peter ^a   Rice, Charles M ^c   McKeating, Jane A ^a   Houghton, Michael ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NOVARTIS   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

E1E2; E2; Guinea pig; HCV; Immunogenicity; Neutralization; p7

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; IMMUNOLOGICAL ADJUVANT; LIPOPROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS REACTION; EPITOPE MAPPING; FEMALE; GENOTYPE; GUINEA PIG; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RODENT; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS STRAIN;

ANIMALS; CELL CULTURE TECHNIQUES; CROSS REACTIONS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; NEUTRALIZATION TESTS; RODENTIA; VIRAL ENVELOPE PROTEINS;

EID: 35348898348     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.053     Document Type: Article

References (93)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
2. Gerlach J.T., Diepolder H.M., Zachoval R., Gruener N.H., Jung M.C., Ulsenheimer A., et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125 (2003) 80-88
3. Villano S.A., Vlahov D., Nelson K.E., Cohn S., and Thomas D.L. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29 (1999) 908-914
4. Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 87 (1990) 6547-6549
5. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42 (2005) 962-973
6. Kuiken C., Yusim K., Boykin L., and Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 21 (2005) 379-384
7. Griffin S.D., Beales L.P., Clarke D.S., Worsfold O., Evans S.D., Jaeger J., et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 535 (2003) 34-38
8. Clarke D., Griffin S., Beales L., Gelais C.S., Burgess S., Harris M., et al. Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro. J Biol Chem 281 (2006) 37057-37068
9. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., et al. Protection against persistence of hepatitis C. Lancet 359 (2002) 1478-1483
10. Weiner A.J., Paliard X., Selby M.J., Medina-Selby A., Coit D., Nguyen S., et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 75 (2001) 7142-7148
11. Bassett S.E., Guerra B., Brasky K., Miskovsky E., Houghton M., Klimpel G.R., et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33 (2001) 1479-1487
12. Lanford R.E., Guerra B., Chavez D., Bigger C., Brasky K.M., Wang X.H., et al. Cross-genotype immunity to hepatitis C virus. J Virol 78 (2004) 1575-1581
13. Houghton M., and Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436 (2005) 961-966
14. Chang K.M., Thimme R., Melpolder J.J., Oldach D., Pemberton J., Moorhead-Loudis J., et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 33 (2001) 267-276
15. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10 (1999) 439-449
16. Cucchiarini M., Kammer A.R., Grabscheid B., Diepolder H.M., Gerlach T.J., Gruner N., et al. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 203 (2000) 111-123
17. Diepolder H.M., Gerlach J.T., Zachoval R., Hoffmann R.M., Jung M.C., Wierenga E.A., et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71 (1997) 6011-6019
18. Lauer G.M., Barnes E., Lucas M., Timm J., Ouchi K., Kim A.Y., et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127 (2004) 924-936
19. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 (2000) 1499-1512
20. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98 (1996) 706-714
21. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 99 (2002) 15661-15668
22. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., and Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 (2001) 1395-1406
23. Bartosch B., Dubuisson J., and Cosset F.L. Infectious Hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197 (2003) 633-642
24. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 100 (2003) 7271-7276
25. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., et al. Complete replication of hepatitis C virus in cell culture. Science 309 (2005) 623-626
26. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (2005) 791-796
27. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102 (2005) 9294-9299
28. Bartosch B., Bukh J., Meunier J.C., Granier C., Engle R.E., Blackwelder W.C., et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 100 (2003) 14199-14204
29. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 101 (2004) 10149-10154
30. Netski D.M., Mosbruger T., Depla E., Maertens G., Ray S.C., Hamilton R.G., et al. Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 41 (2005) 667-675
31. Meunier J.C., Engle R.E., Faulk K., Zhao M., Bartosch B., Alter H., et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci USA 102 (2005) 4560-4565
32. Allander T., Beyene A., Jacobson S.H., Grillner L., and Persson M.A. Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response. J Infect Dis 175 (1997) 26-31
33. Isaguliants M.G., Widell A., Zhang S.M., Sidorchuk A., Levi M., Smirnov V.D., et al. Antibody responses against B-cell epitopes of the hypervariable region 1 of hepatitis C virus in self-limiting and chronic human hepatitis C followed-up using consensus peptides. J Med Virol 66 (2002) 204-217
34. Ishii K., Rosa D., Watanabe Y., Katayama T., Harada H., Wyatt C., et al. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28 (1998) 1117-1120
35. Zibert A., Kraas W., Meisel H., Jung G., and Roggendorf M. Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol 71 (1997) 4123-4127
36. Zibert A., Meisel H., Kraas W., Schulz A., Jung G., and Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 25 (1997) 1245-1249
37. Pestka J.M., Zeisel M.B., Blaser E., Schurmann P., Bartosch B., Cosset F.-L., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. PNAS 104 (2007) 6025-6030
38. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79 (2005) 6023-6034
39. Von Hahn T., Yoon J.C., Alter H., Rice C.M., Rehermann B., Balfe P., et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132 (2007) 667-678
40. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris H, et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology, doi:10.1002/hep.21959.
41. Choo Q.L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 91 (1994) 1294-1298
42. Rosa C., Osborne S., Garetto F., Griva S., Rivella A., Calabresi G., et al. Epitope mapping of the NS4 and NS5 gene products of hepatitis C virus and the use of a chimeric NS4-NS5 synthetic peptide for serodiagnosis. J Virol Methods 55 (1995) 219-232
43. Coates S., Choo Q.L., Kuo G., Crawford K., Dong C., Wininger M., et al. In: Jilbert A.R., Grgacic E.V.L., Vickery K., Burrell C.J., and Cossart Y.E. (Eds). Proceedings of the 11th International Symposium on Viral Hepatitis and Liver Disease (2005) 118-123
44. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 93 (1996) 15394-15399
45. Major M.E., Mihalik K., Puig M., Rehermann B., Nascimbeni M., Rice C.M., et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 76 (2002) 6586-6595
46. Puig M., Major M.E., Mihalik K., and Feinstone S.M. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22 (2004) 991-1000
47. Goto J., Nishimura S., Esumi M., Makizumi K., Rikihisa T., Nishihara T., et al. Prevention of hepatitis C virus infection in a chimpanzee by vaccination and epitope mapping of antiserum directed against hypervariable region 1. Hepatol Res S 19 (2001) 270-283
48. Youn J.W., Park S.H., Lavillette D., Cosset F.L., Yang S.H., Lee C.G., et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42 (2005) 1429-1436
49. Christie J.M., Healey C.J., Watson J., Wong V.S., Duddridge M., Snowden N., et al. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol 110 (1997) 4-8
50. Chapel H.M., Christie J.M., Peach V., and Chapman R.W. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 99 (2001) 320-324
51. McKeating J.A., Zhang L.Q., Logvinoff C., Flint M., Zhang J., Yu J., et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virology 78 (2004) 8496-8505
52. Krawczynski K., Alter M.J., Tankersley D.L., Beach M., Robertson B.H., Lambert S., et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 173 (1996) 822-828
53. Phogat S., Wyatt R.T., and Karlsson Hedestam G.B. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med 262 (2007) 26-43
54. Brandriss M.W., Schlesinger J.J., Walsh E.E., and Briselli M. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 67 (1986) 229-234
55. Bray M., and Lai C.J. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology 185 (1991) 505-508
56. Konishi E., Pincus S., Paoletti E., Shope R.E., Burrage T., and Mason P.W. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 188 (1992) 714-720
57. Kaplan D.E., Sugimoto K., Newton K., Valiga M.E., Ikeda F., Aytaman A., et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology S 132 (2007) 654-666
58. Dubuisson J., Duvet S., Meunier J.C., Op De Beeck A., Cacan R., Wychowski C., et al. Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein. J Biol Chem 275 (2000) 30605-30609
59. Blight K.J., McKeating J.A., and Rice C.M. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76 (2002) 13001-13014
60. Flint M., Maidens C., Loomis-Price L.D., Shotton C., Dubuisson J., Monk P., et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73 (1999) 6235-6244
61. Tscherne D.M., Jones C.T., Evans M.J., Lindenbach B.D., McKeating J.A., and Rice C.M. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 80 (2006) 1734-1741
62. Bartosch B., Verney G., Dreux M., Donot P., Morice Y., Penin F., et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79 (2005) 8217-8229
63. Dreux M., Pietschmann T., Granier C., Voisset C., Ricard-Blum S., Mangeot P.E., et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 281 (2006) 18285-18295
64. Voisset C., Op de Beeck A., Horellou P., Dreux M., Gustot T., Duverlie G., et al. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol 87 (2006) 2577-2581
65. Rosa D., Campagnoli S., Moretto C., Guenzi E., Cousens L., Chin M., et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 93 (1996) 1759-1763
66. Bartosch B., and Cosset F.L. Cell entry of hepatitis C virus. Virology 348 (2006) 1-12
67. Cocquerel L., Voisset C., and Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol 87 (2006) 1075-1084
68. Tarr A.W., Owsianka A.M., Timms J.M., McClure C.P., Brown R.J., Hickling T.P., et al. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43 (2006) 592-601
69. Heile J.M., Fong Y.L., Rosa D., Berger K., Saletti G., Campagnoli S., et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol 74 (2000) 6885-6892
70. Martinez-Donato G., Capdesuner Y., Acosta-Rivero N., Rodriguez A., Morales-Grillo J., Martinez E., et al. Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice. Mol Biotechnol 35 (2007) 225-235
71. Abraham J.D., Himoudi N., Kien F., Berland J.L., Codran A., Bartosch B., et al. Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine 22 (2004) 3917-3928
72. Majid A.M., Ezelle H., Shah S., and Barber G.N. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. J Virol 80 (2006) 6993-7008
73. Netter H.J., Macnaughton T.B., Woo W.P., Tindle R., and Gowans E.J. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol 75 (2001) 2130-2141
74. Elmowalid G.A., Qiao M., Jeong S.H., Borg B.B., Baumert T.F., Sapp R.K., et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 104 (2007) 8427-8432
75. Fournillier A., Nakano I., Vitvitski L., Depla E., Vidalin O., Maertens G., et al. Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes. Hepatology 28 (1998) 237-244
76. Forns X., Emerson S.U., Tobin G.J., Mushahwar I.K., Purcell R.H., and Bukh J. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 17 (1999) 1992-2002
77. Forns X., Payette P.J., Ma X., Satterfield W., Eder G., Mushahwar I.K., et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32 (2000) 618-625
78. Ma X., Forns X., Gutierrez R., Mushahwar I.K., Wu T., Payette P.J., et al. DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine 20 (2002) 3263-3271
79. Lee S.W., Cho J.H., and Sung Y.C. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 72 (1998) 8430-8436
80. Lechmann M., and Liang T.J. Vaccine development for hepatitis C. Semin Liver Dis 20 (2000) 211-226
81. Fournillier A., Depla E., Karayiannis P., Vidalin O., Maertens G., Trepo C., et al. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol 73 (1999) 7497-7504
82. Burioni R., Bugli F., Mancini N., Rosa D., Di Campli C., Moroncini G., et al. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology 288 (2001) 29-35
83. Bugli F., Mancini N., Kang C.Y., Di Campli C., Grieco A., Manzin A., et al. Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol 75 (2001) 9986-9990
84. Nevens F., Roskams T., Van Vlierberghe H., Horsmans Y., Sprengers D., Elewaut A., et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38 (2003) 1289-1296
85. Leroux-Roels G., Batens A.H., Desombere I., Van Den Steen B., Vander Stichele C., Maertens G., et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 1 (2005) 61-65
86. Vietheer P.T., Boo I., Drummer H.E., and Netter H.J. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir Ther 12 (2007) 477-487
87. Torresi J., Stock O.M., Fischer A.E., Grollo L., Drummer H., Boo I., et al. A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus. Hepatology 45 (2007) 911-920
88. Schofield D.J., Bartosch B., Shimizu Y.K., Allander T., Alter H.J., Emerson S.U., et al. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42 (2005) 1055-1062
89. Allander T., Forns X., Emerson S.U., Purcell R.H., and Bukh J. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins. Virology 277 (2000) 358-367
90. Eren R., Landstein D., Terkieltaub D., Nussbaum O., Zauberman A., Ben-Porath J., et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 80 (2006) 2654-2664
91. Keck Z.Y., Li T.K., Xia J., Bartosch B., Cosset F.L., Dubuisson J., et al. Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol 79 (2005) 13199-13208
92. Keck Z.Y., Xia J., Cai Z., Li T.K., Owsianka A.M., Patel A.H., et al. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 81 (2007) 1043-1047
93. Burioni R., Mancini N., Carletti S., Perotti M., Grieco A., Canducci F., et al. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. Virology 327 (2004) 242-248